Last reviewed · How we verify

NCT01788722

Regulatory Post Marketing Surveillance Study in Korea

Completed Last updated 2 August 2018
What this trial tests

trial testing Dienogest (Visanne, BAY86-5258) in Endometriosis in 3,223 participants. Completed in 11 August 2017.

Timeline
19 July 2013
Primary endpoint
11 August 2017
11 August 2017

Quick facts

Lead sponsorBayer
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,223
Start date19 July 2013
Primary completion11 August 2017
Estimated completion11 August 2017
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Bayer — full company profile →

Who can join

Eligibility, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to investigate and collect post marketing data on the safety and efficacy of Visanne at follow-up visit after about 6 months of treatment and - for a subset of patients - at optional long-term follow-up visit after about 1 year of treatment under daily practice treatment conditions in Korean women and to obtain data on drug utilization on treatment for endometriosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dienogest (Visanne, BAY86-5258)

Trials testing the same drug.

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

Other Bayer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01788722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing